Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?

Turinetto, M; Ray-Coquard, I; Gourley, C

Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?

Turinetto, M; Ray-Coquard, I; Gourley, C.

Afiliação

Turinetto M; Department of Oncology, University of Torino at Ordine Mauriziano Hospital, Turin, Italy. Electronic address: margherita.turinetto@gmail.com.
Ray-Coquard I; Centre Léon Bérard Department of Medicine and Centre de Recherche en Cancérologie de Lyon, Lyon Recherche Innovation Contre le Cancer (LYRICAN), Université Claude Bernard Lyon I, Lyon, France.
Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

ESMO Open ; 9(5): 102983, 2024 May.

Article em En | MEDLINE | ID: mdl-38663167

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica; Bevacizumab; Humanos; Bevacizumab/uso terapêutico; Bevacizumab/farmacologia; Feminino; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia; Quimioterapia de Manutenção/métodos; Mutação; Proteína BRCA1/genética; Proteína BRCA2/genética; Neoplasias Ovarianas/tratamento farmacológico; Neoplasias Ovarianas/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab Limite: Female / Humans Idioma: En Revista: ESMO Open Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google